• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial comment on: "".

作者信息

Ahn Daniel H, Bekaii-Saab Tanios

机构信息

Division of Hematology/Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

出版信息

Hepatobiliary Surg Nutr. 2022 Feb;11(1):112-114. doi: 10.21037/hbsn-21-469.

DOI:10.21037/hbsn-21-469
PMID:35284514
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8847863/
Abstract
摘要

相似文献

1
Editorial comment on: "".关于“”的编辑评论。
Hepatobiliary Surg Nutr. 2022 Feb;11(1):112-114. doi: 10.21037/hbsn-21-469.
2
An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.欧洲肝脏研究学会关于肝细胞癌全身治疗的立场文件：勇往直前。
J Hepatol. 2022 Feb;76(2):478-480. doi: 10.1016/j.jhep.2021.08.023. Epub 2021 Sep 4.
3
Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously".
J Hepatol. 2022 Feb;76(2):480-481. doi: 10.1016/j.jhep.2021.10.021. Epub 2021 Nov 2.
4
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.EASL 和 mRECIST 评价索拉非尼联合经动脉化疗栓塞治疗肝细胞癌的疗效反应可预测患者的生存。
Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.
5
EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.EASL 和 mRECIST 应答是接受冷冻消融治疗的肝细胞癌患者生存的独立预测因素。
Eur J Gastroenterol Hepatol. 2013 May;25(5):620-7. doi: 10.1097/MEG.0b013e32835ced13.
6
Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?在多期CT中应用哪些标准可以预测接受传统经动脉化疗栓塞术（TACE）治疗的肝细胞癌患者的早期肿瘤反应：RECIST、mRECIST、EASL还是qEASL？
Cardiovasc Intervent Radiol. 2018 Mar;41(3):433-442. doi: 10.1007/s00270-017-1829-4. Epub 2017 Oct 30.
7
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.单独或联合使用 EASL、RECIST 和 WHO 反应指南在肝细胞癌中的作用：放射病理相关性。
J Hepatol. 2011 Apr;54(4):695-704. doi: 10.1016/j.jhep.2010.10.004. Epub 2010 Oct 23.
8
Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.回顾性比较 EASL 2018 与 LI-RADS 2018 对磁共振成像诊断肝细胞癌的非侵入性诊断价值。
Hepatol Int. 2020 Jan;14(1):70-79. doi: 10.1007/s12072-019-10002-3. Epub 2019 Dec 4.
9
Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma.人还是机器？2018 年 EASL、LI-RADS 标准与基于影像组学模型对肝细胞癌诊断的前瞻性比较
Cancer Imaging. 2019 Dec 5;19(1):84. doi: 10.1186/s40644-019-0266-9.
10
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.甲胎蛋白应答与孤立性肝细胞癌经肝动脉治疗的 EASL 应答和生存相关：亚组分析。
J Hepatol. 2012 May;56(5):1112-1120. doi: 10.1016/j.jhep.2011.11.020. Epub 2012 Jan 13.

本文引用的文献

1
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.系统治疗与晚期肝细胞癌的序贯治疗选择：系统评价和网络荟萃分析。
JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10.
2
Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.卡博替尼可抑制由生长停滞特异性蛋白6和肝细胞生长因子诱导的、AXL和MET依赖性的癌细胞迁移。
Biochem Biophys Rep. 2020 Jan 17;21:100726. doi: 10.1016/j.bbrep.2020.100726. eCollection 2020 Mar.
3
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
5
Cabozantinib in Hepatocellular Carcinoma.卡博替尼治疗肝细胞癌
N Engl J Med. 2018 Oct 4;379(14):1384-1385. doi: 10.1056/NEJMc1810178.
6
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
7
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
8
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.靶向MET和AXL可克服肾细胞癌对舒尼替尼治疗的耐药性。
Oncogene. 2016 May;35(21):2687-97. doi: 10.1038/onc.2015.343. Epub 2015 Sep 14.
9
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.